OnKure Therapeutics, Inc. (OKUR) NASDAQ
4.61
+0.155(+3.48%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.61
+0.155(+3.48%)
Currency In USD
| Previous Close | 4.45 |
| Open | 4.58 |
| Day High | 4.7 |
| Day Low | 4.56 |
| 52-Week High | 4.75 |
| 52-Week Low | 1.7 |
| Volume | 219,112 |
| Average Volume | 288,193 |
| Market Cap | 62.97M |
| PE | -1.04 |
| EPS | -4.42 |
| Moving Average 50 Days | 3.37 |
| Moving Average 200 Days | 2.91 |
| Change | 0.16 |
OnKure Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., Presiden
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
GlobeNewswire Inc.
Mar 04, 2025 1:00 PM GMT
BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinica